Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: The HUNT study

Clinical Chemistry

Volumn 61, Issue 4, 2015, Pages 646-656

  Omland, Torbjørn ^a,b   De Lemos, James A ^c   Holmen, Oddgeir L ^d   Dalen, Håvard ^d,e   Benth, Jurate Šaltyte ^a,b   Nygård, Ståle ^b,f   Hveem, Kristian ^d   Røsjø, Helge ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e Levanger Hospital   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY ASSAY FOR CARDIAC TROPONIN I; TRIACYLGLYCEROL; TROPONIN I; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; POPULATION; PREVALENCE; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; COHORT ANALYSIS; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; NORWAY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NORWAY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; ROC CURVE; SEX FACTORS; TROPONIN I; YOUNG ADULT;

EID: 84925726192     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.234369     Document Type: Article

References (37)

1. Whelton PK. Epidemiology of hypertension. Lancet 1994; 344:101-6.
2. de Simone G, Devereux RB, Daniels S.R., Meyer RA. Gender differences in left ventricular growth. Hypertension 1995; 26:979-83.
3. Kannel WB, Hjortland MC, McNamara P.M., Gordon T. References Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976; 85:447-52.
4. Omland T. New features of troponin testing in different clinical settings. J Intern Med 2010; 268:207-17.
5. de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA 2013; 309:2262-9.
6. de Lemos JA, Drazner MH, Omland T, Ayers C.R., Khera A., Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503-12.
7. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010; 304:2494-502.
8. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011; 123: 1367-76.
9. Wang TJ, Wollert KC, Larson M.G., Coglianese E., McCabe EL, Cheng S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012; 126:1596-604.
10. Eggers KM, Venge P, Lindahl B., Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol 2013; 61:1906-13.
11. Zeller T, Tunstall-Pedoe H, Saarela O., Ojeda F, Schnabel RB, Tuovinen T, et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J 2014; 35: 271-81.
12. Gore MO, Seliger SL, Defilippi C.R., Nambi V., Christenson RH, Hashim IA, et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol 2014; 63:1441-8.
13. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012; 58:1574-81.
14. Krokstad S, Langhammer A, Hveem K., Holmen TL, Midthjell K, Stene TR, et al. Cohort profile: the HUNT Study, Norway. Int J Epidemiol 2013; 42:968-77.
15. Koerbin G, Tate J, Potter J.M., Cavanaugh J., Glasgow N, Hickman PE. Characterisation of a highly sensitive troponin I assay and its application to a cardio-healthy population. Clin Chem Lab Med 2012; 50:871-8.
16. Rezvanpour A, Shortt C, Clark L., Worster A, Kavsak PA. Analytical factors to consider when assessing a high-sensitivity cardiac troponin I assay compared to a contemporary assay in clinical studies. Clin Chim Acta 2014; 429:6-7.
17. Omland T, Pfeffer MA, Solomon S.D., de Lemos JA, Røsjø H, Saltyte Benth J, et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients withstable coronaryartery disease. J Am Coll Cardiol 2013; 61:1240-9.
18. Røsjø H, Kravdal G, Høiseth AD, Jørgensen M, Badr P, Røysland R, et al. Troponin I measured by a high-sensitivity assay in patients with suspected reversible myocardial ischemia: data from the Akershus Cardiac Examination (ACE) 1 study. Clin Chem 2012; 58:1565-73.
19. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58:54-61.
20. Levey AS, Bosch JP, Lewis J.B., Greene T., Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70.
21. Laugsand LE, Asvold BO, Vatten L.J., Romundstad PR, Wiseth R, Hveem K, et al. Metabolic factors and high-sensitivity C-reactive protein: the HUNT study. Eur J Prev Cardiol 2012; 19:1101-10.
22. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23:2109-23.
23. Greenslade JH, Kavsak P, Parsonage W., Shortt C, Than M, Pickering J.W., et al. Combining presentation high-sensitivity cardiac troponin I and glucose measurements to rule-out an acute myocardial infarction in patients presenting to emergency department with chest pain. Clin Biochem [Epub ahead of print 2014 Dec 5].
24. Thygesen K, Alpert JS, Jaffe A.S., Simoons ML, Chaitman BR, White HD, at al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33:2551-67.
25. White HD. Pathobiology oftroponin elevations: doelevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol 2011; 57:2406-8.
26. Neeland IJ, Drazner MH, Berry J.D., Ayers CR, deFilippi C, Seliger SL, et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. J Am Coll Cardiol 2013; 61:187-95.
27. Røsjø H, Andreassen J, Edvardsen T, Omland T. Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardio-graphic indexes of cardiac function and anatomy. Am J Cardiol 2011; 108:88-91.
28. Evans JM, Ziegler MG, Patwardhan A.R., Ott JB, Kim CS, Leonelli FM, et al. Gender differencesin autonomic cardiovascular regulation: spectral, hormonal, and hemodynamic indexes. J Appl Physiol 2001; 91:2611-8.
29. Donaldson C, Eder S, Baker C., Aronovitz MJ, Weiss AD, Hall-Poter M, et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res 2009; 04:265-75.
30. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski K.A., et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009; 361:2538-47.
31. Kavsak PA, Xu L, Yusuf S, McQueen MJ. High-sensitivity cardiac troponin Imeasurement for risk stratification in a stable high-risk population. Clin Chem 2011; 57: 1146-53.
32. McQueen MJ, Kavsak PA, Xu L, Shestakovska O., Yusuf S. Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. Clin Biochem 2013; 46:5-9.
33. Vaccarino V, Badimon L, Corti R., de Wit C, Dorobantu M, Manfrini O., et al. Presentation, management, and outcomes of ischaemic heart disease in women. Nat Rev Cardiol 2013; 10:508-18.
34. Eggers KM, Johnston N, James S., Lindahl B, Venge P. Cardiac troponin I levels in patients with non-ST-elevation acute coronary syndrome: the importance of gender. Am Heart J 2014; 168:317-24.
35. Kavsak PA, Xu L, Shortt C., Pond G, Worster A. High-sensitivity cardiac troponin I for predicting death in a female emergency department population population. Clin Chem 2014; 60:271-3.
36. White HD, Tonkin A, Simes J., Stewart R, Mann K, Thompson P., et al. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). J Am Coll Cardiol 2014; 63:345-54.
37. Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004; 255:494-502.